BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36178950)

  • 1. CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients.
    Dalle Fratte C; Gagno S; Roncato R; Polesel J; Zanchetta M; Buzzo M; Posocco B; De Mattia E; Borsatti R; Puglisi F; Foltran L; Guardascione M; Buonadonna A; Cecchin E; Toffoli G
    Br J Clin Pharmacol; 2023 Mar; 89(3):1089-1098. PubMed ID: 36178950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Informative Are Drug-Drug Interactions of Gene-Drug Interactions?
    Lagishetty CV; Deng J; Lesko LJ; Rogers H; Pacanowski M; Schmidt S
    J Clin Pharmacol; 2016 Oct; 56(10):1221-31. PubMed ID: 27040602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.
    Bahar MA; Setiawan D; Hak E; Wilffert B
    Pharmacogenomics; 2017 May; 18(7):701-739. PubMed ID: 28480783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
    Adehin A; Adeagbo BA; Kennedy MA; Bolaji OO; Olugbade TA; Bolarinwa RA; Durosinmi MA
    Leuk Lymphoma; 2019 Jan; 60(1):216-221. PubMed ID: 29741432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
    Verboom MC; Visser L; Kouwen S; Swen JJ; Diepstraten J; Posthuma WF; Gelderblom H; van Lammeren D; Wilms EB
    Pharmacogenet Genomics; 2017 Jun; 27(6):223-226. PubMed ID: 28383355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
    López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
    Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
    Barratt DT; Cox HK; Menelaou A; Yeung DT; White DL; Hughes TP; Somogyi AA
    Clin Pharmacokinet; 2017 Aug; 56(8):977-985. PubMed ID: 27995529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
    Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital.
    McGrane IR; Loveland JG
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):395-9. PubMed ID: 26871369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
    Lu S; Nand RA; Yang JS; Chen G; Gross AS
    Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between genetic polymorphisms and variation of imatinib pharmacokinetics in gastrointestinal stromal tumors].
    Qiu H; Zhuang W; Wang X; Huang M; Zhou Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1031-1034. PubMed ID: 28900995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population.
    Hahn M; Müller DJ; Roll SC
    Pharmacopsychiatry; 2021 Mar; 54(2):81-89. PubMed ID: 33327018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.
    Manworren RC; Jeffries L; Pantaleao A; Seip R; Zempsky WT; Ruaño G
    Clin J Pain; 2016 Feb; 32(2):109-15. PubMed ID: 25803758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.
    Pena MÁ; Muriel J; Saiz-Rodríguez M; Borobia AM; Abad-Santos F; Frías J; Peiró AM
    Clin Drug Investig; 2020 Jul; 40(7):617-628. PubMed ID: 32415468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
    Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping.
    Verbeurgt P; Mamiya T; Oesterheld J
    Pharmacogenomics; 2014 Apr; 15(5):655-65. PubMed ID: 24798722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.